ResearchMoz

Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though High Unmet Need Remains

GBI Research
Published Date » 2013-10-31
No. Of Pages » N/A
   
 GBI Research has released its research, “ Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though High Unmet Need Remains”, which provides in-depth insights into the macular degeneration market forecast until 2019 for the Asia-Pacific (APAC) region covering the four countries of Australia, China, India and Japan. It also covers disease epidemiology; treatment algorithms; treatment patterns; an in-depth analysis of clinical trials including failure rate analysis, pipeline analysis; and an analysis of deals relevant to macular degeneration. Apart from these the report also includes a heat map for the macular degeneration marketed products.  
   
 GBI Research analysis shows that the APAC ophthalmology market...
Table of Content

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Macular Degeneration Asia-Pacific Market to 2019 – Introduction
2.1 Symptoms
2.2 Etiology
2.3 Pathophysiology
2.3.1 Disease Initiation
2.3.2 Disease Propagation
2.4 Classification
2.4.1 Early AMD
2.4.2 Intermediate AMD
2.4.3 Advanced AMD
2.5 Co-morbidities and Complications
2.6 Diagnosis
2.6.1 History
2.6.2 Examination
2.6.3 Diagnostic Tests
2.7 Epidemiology
2.8 Prognosis and Disease Staging
2.9 Treatment Options
2.9.1 Pharmacological
2.9.2 Treatment Algorithms and Prescribing Habits
2.9.3 Non-pharmacological Care

3 Macular Degeneration Asia-Pacific Market to 2019 – Marketed Products
3.1 Therapeutic Landscape
3.1.1 Lucentis (ranibizumab) – Novartis AG/Roche (Genentech)
3.1.2 Eylea (aflibercept) – Regeneron Pharmaceuticals/Bayer Healthcare
3.1.3 Avastin (bevacizumab) – Genentech (Roche)
3.1.4 Macugen (pegaptanib sodium) – Valeant Pharmaceuticals/Pfizer
3.1.5 Visudyne (verteporfin injection) – Novartis AG
3.1.6 Triamcinolone Acetonide
3.2 Comparative Efficacy and Safety

4 Macular Degeneration Asia-Pacific Market to 2019 – Pipeline for Disease
4.1 Overall Pipeline
4.2 Pipeline Analysis by Molecule Type
4.3 Pipeline Analysis by Mechanism of Action
4.4 Clinical Trials
4.4.1 Failure Rate
4.4.2 Clinical Trial Duration
4.4.3 Clinical Trial Size
4.5 Promising Drug Candidates in the Pipeline
4.5.1 MC-1101 – MacuCLEAR, Inc.
4.5.2 KH902 (Fumintide) – Chengdu Kanghong Pharmaceuticals Group Co., Ltd.

5 Macular Degeneration Asia-Pacific Market to 2019 – Market Forecast to 2019
5.1 Geographical Markets
5.1.1 APAC Market
5.1.2 Australia
5.1.3 China
5.1.4 India
5.1.5 Japan
5.2 Drivers and Barriers for the Disease Market
5.2.1 Drivers
5.2.2 Barriers

6 Macular Degeneration Asia-Pacific Market to 2019 – Deals and Strategic Consolidations
6.1 Deals Analysis
6.2 Major Co-development Deals
6.2.1 Sinphar Enters into Co-development Agreement with MacuCLEAR
6.2.2 Allergan Enters into Co-development Agreement with Molecular Partners
6.2.3 X-Body BioSciences Enters into Co-development Agreement with Hengrui Medicine for AMD
6.2.4 Alcon Enters into Collaboration with AstraZeneca
6.2.5 Acucela Enters into Co-Development Agreement with Otsuka Pharma for ACU-4429
6.3 Major Licensing Deals
6.3.1 Allegro Ophthalmics Enters into Licensing Agreement with Senju Pharma to Develop Integrin Peptide Therapy
6.3.2 Allergan Enters into Licensing Agreement with Molecular Partners
6.3.3 PanOptica Enters into Licensing Agreement with OSI Pharma
6.3.4 Lpath Enters into Licensing Agreement with Pfizer
6.3.5 Shionogi Enters into Licensing Agreement with OncoTherapy Science

7 Macular Degeneration Asia-Pacific Market to 2019 – Appendix
7.1 All Pipeline Drugs by Phase
7.1.1 Discovery
7.1.2 Preclinical
7.1.3 IND-filed and Phase 0
7.1.4 Phase I
7.1.5 Phase II
7.1.6 Phase III
7.1.7 Undisclosed
7.2 Market Forecasts to 2019
7.2.1 Asia-Pacific
7.2.2 Australia
7.2.3 China
7.2.4 India
7.2.5 Japan
7.3 Market Definitions
7.4 Abbreviations
7.5 References
7.6 Research Methodology
7.6.1 Coverage
7.6.2 Secondary Research
7.6.3 Primary Research
7.6.4 Therapeutic Landscape
7.6.5 Geographical Landscape
7.6.6 Pipeline Analysis
7.7 Expert Panel Validation
7.8 Contact Us
7.9 Disclaimer

List of Tables


Table 1: Macular Degeneration Market, Classification of AMD
Table 2: Macular Degeneration Market, Treatment Recommendations and Follow-up for Non-neovascular AMD
Table 3: Macular Degeneration Market, Treatment Recommendations and Follow-up for Neovascular AMD
Table 4: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Discovery), 2013
Table 5: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Preclinical), 2013
Table 6: Macular Degeneration Market, Global, Pharmaceutical Pipeline (IND/CTA-filed), 2013
Table 7: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Phase I), 2013
Table 8: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Phase II), 2013
Table 9: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Phase III), 2013
Table 10: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Undisclosed), 2013
Table 11: Macular Degeneration Market, Asia-Pacific, Market Forecast, 2012–2019
Table 12: Macular Degeneration Market, Australia, Market Forecast, 2012–2019
Table 13: Macular Degeneration Market, China, Market Forecast, 2012–2019
Table 14: Macular Degeneration Market, India, Market Forecast, 2012–2019
Table 15: Macular Degeneration Market, Japan, Market Forecast, 2012–2019

List of Figures


Figure 1: Macular Degeneration Market, Pathophysiology of AMD
Figure 2: Macular Degeneration Market, Types of Dry AMD
Figure 3: Macular Degeneration Market, Classification of AMD
Figure 4: Macular Degeneration Market, Amsler Grid Test
Figure 5: Macular Degeneration Market, Asia-Pacific, Epidemiology, 2012–2019
Figure 6: Macular Degeneration Market, Photodynamic Therapy
Figure 7: Macular Degeneration Market, Treatment Algorithm by Type and by Stage
Figure 8: Macular Degeneration Market, Fluorescein Angiogram Showing Laser Photocoagulation Images
Figure 9: Macular Degeneration Market, Global, Annual Sales ($m), 2012
Figure 10: Macular Degeneration Market, Lucentis, Global, Annual Sales ($m), 2006–2012
Figure 11: Macular Degeneration Market, Eylea, Global, Annual Sales ($m), 2011–2012
Figure 12: Macular Degeneration Market, Visudyne, Global, Annual Sales ($m), 2005–2012
Figure 13: Macular Degeneration, Global, Heat Map of Safety and Efficacy for Marketed Products
Figure 14: Macular Degeneration Market, Global, Pipeline, 2013
Figure 15: Macular Degeneration Market, Global, Pipeline, 2013
Figure 16: Macular Degeneration Market, Global, Pipeline, 2013
Figure 17: Macular Degeneration Market, Global, Clinical Trial Failure Rate, 2013
Figure 18: Macular Degeneration Market, Global, Pipeline, Clinical Trial Duration, 2013
Figure 19: Macular Degeneration Market, Global, Pipeline, Clinical Trial Size, 2013
Figure 20: Macular Degeneration Market, Global, Annual Sales ($bn), 2012–2019
Figure 21: Macular Degeneration Market, Australia, Annual Sales ($m), 2012–2019
Figure 22: Macular Degeneration Market, China, Annual Sales ($m), 2012–2019
Figure 23: Macular Degeneration Market, India, Annual Sales ($m), 2012–2019
Figure 24: Macular Degeneration Market, Japan, Annual Sales ($m), 2012–2019
Figure 25: Macular Degeneration Market, Global, Deals, 2007–2013
Figure 26: Macular Degeneration Market, Global, Co-development Deals, 2007–2013
Figure 27: Macular Degeneration Market, Global, Licensing Deals, 2007–2013
Figure 28: GBI Research Market Forecasting Model

Upcoming Reports:

Mexico Ophthalmic Devices Market: Industry Size, Market Share, Trends,Analysis And Forecasts 2012 - 2018
By - Transparency Market Research
SCOPE OF THE REPORT This report is an effort to identify factors, which will be the driving force behind the ophthalmic devices market and sub-markets in the next six years. This report is specially designed to estimate and analyze the demand and performance of Mexican ophthalmic devices market. The report provides extensive analysis of the ophthalmic devices industry, current market trends, industry drivers and challenges for better understanding of the ophthalmic devices market structure. The report has segregated the ophthalmic devices industry in terms of...
Infusion Systems Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
An Infusion system is a device and any associated disposable used to deliver fluids, medication or nutrients in to the patient’s circulatory system. The most common route of administration of such products in patients is intravenous and is followed by subcutaneous, epidural or enteral route. Infusion systems are categorized into in five market segments namely, syringe pumps, infusion disposable sets, implantable infusion pumps, volumetric pumps and ambulatory infusion pumps.  Infusion systems are basically designed to administer fluids which are otherwise...
Cardiopulmonary Stress Testing Systems Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Cardiopulmonary stress test (CPST) is performed in order to measure gas exchange i.e. the amount of oxygen inhaled and the amount of carbon dioxide exhaled. It is generally performed on a treadmill or a special type of bicycle with a unique mouthpiece to measure gas exchange. It provides information about body’s response to exercise. A cardiopulmonary stress test evaluates well how your heart and lungs work individually and in unison. This test is performed for a variety of reasons such as to detect heart failure, ischemic heart disease, shortness of breath and other pulmonary...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Ford Recalls 65,000 Fusion Models Due to Issues in Ignition Key
Nov 20, 2014  
If anything defines the world of automobiles currently, it would be recalls. It seems that a flood of automobiles has surrounded the global automobiles industry, which once represented a flourishing and highly profitable industry.  The current automobile giants ordering yet another recall is Ford Motors Co. Ford declared on Tuesday that it is recalling nearly 65,000 sedans from...
3D Printed Heart Model for Better Cardiological Treatment
Nov 20, 2014  
According to research carried out by the American Heart Association’s Scientific Sessions 2014, surgeons will be able to treat complex heart disorders in patients, with the help of a three dimensional experimental printed model of the heart. For surgical planning, most cardiac surgeons make use of two dimensional images of the heart taken by MRI, ultrasound, and X-ray. But the problem is...
Los Angeles Auto Show Kicks Off
Nov 20, 2014  
The Los Angeles Auto Show kicked off on Wednesday with a rather upbeat mood. Motoring machines, industry metrics, and hybrid models – the show has lived up to its reputation once more. The Los Angeles Auto Show has begun touring North America from the Los Angeles Convention Center, and the commencement has already had an impact on the market. Gasoline prices dropped under US$3...
Scottish Government to Inject 200 Million Pounds in the Housing Sector
Nov 19, 2014  
The construction and the housing industries of Scotland will get a major financial boost from the Scottish government in terms of additional funding worth 200 million pounds. The main rationale of such a financial boost is to stimulate the housing sector and also safeguarding employment in the construction industry. The housing minister of Scotland has requested the housing leaders to work...
Quarterly Dividend of $0.10 Declared by Tyson Foods, Inc.
Nov 19, 2014  
A quarterly dividend on November 18th was declared by Tyson Foods, reported Analyst Ratings Network.com. The shareholders of the February 27th record will be awarded a dividend of 0.10 per share on March 13th.  This represents a yield of 0.94% and a $0.40 dividend on an annualized basis. However, the ex-dividend date of this particular dividend is February 25th.  Such...